Capecitabine 2000mg/m2/day days 1-14 Cisplatin 60mg/m2 day1 Docetaxel 30mg/m2 or 40mg/m2 day1 every 3 weeks

2 trials

Sponsors

Department of Gastroenterology, Nagoya University Graduate School of Medicine, Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital

Conditions

Gastric cancer

Unknown Phase

A feasibility study of docetaxel + cisplatin + capecitabine (DCX) therapy for unresectable advanced gastric cancer

Active, not recruitingJPRN-UMIN000006009

Department of Gastroenterology, Nagoya University Graduate School of MedicineGastric cancer

Start: 2011-08-01Target: 6Updated: 2026-06-29

Phase II trial of docetaxel+cisplatin+capecitabine (DCX) therapy for unresectable or recurrent HER2-negative gastric cancer

Active, not recruitingJPRN-UMIN000026722

Department of Clinical Oncology and Chemotherapy, Nagoya University HospitalGastric cancer

Start: 2017-05-26Target: 35Updated: 2026-06-29